drugset / Trial / NCT04047693

Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma

NCT04047693 ↗

Phase 2 Terminated 24 enrolled Pusan National University Yangsan Hospital
NaSingle-groupOpen-labelTreatment

Summary

The objective is to investigate the efficacy and safety of four cycles of ddMVAC with G-CSF support in patients with MIBC and locally advanced UC

Timeline

Start
2019-05-01
Primary completion
2022-01-31
Completion
2023-10-31

Outcome

Met primary endpoint

Stopped (Enrollment): “Poor accrual due to increased use of alternative neoadjuvant treatment options.”

paper Overall, 49% (80% CI, 38 to 61) achieved PaR of ≤ pT1N0M0, and we concluded this regimen was effective. PMID 24821883 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 70 mg/m2 Intravenous
Subject Doxorubicin Other / unclassified 30 mg/m2 Intravenous
Subject Methotrexate Small molecule 30 mg/m2 Intravenous
Subject Vinblastine Small molecule 3 mg/m2 Intravenous
Background Pegfilgrastim Protein / enzyme biologic 6 mg Subcutaneous